In aggressive forms of breast cancer, EZH2 acts as a differential molecule by serving as a transcriptional repressor of nuclear factor kappa B (NF-κB) target genes in estrogen receptor (ER)-negative and ER-positive breast cancer cell lines [17]. This evidence concerns the gene ESR1 and breast carcinoma.